Provectus Biopharmaceuticals, Inc. (OTCMKTS:PVCT) Sees Large Increase in Short Interest

Provectus Biopharmaceuticals, Inc. (OTCMKTS:PVCT) was the recipient of a significant growth in short interest in December. As of December 31st, there was short interest totaling 801,174 shares, a growth of 16,004.0% from the December 15th total of 4,975 shares. Based on an average daily trading volume, of 642,736 shares, the short-interest ratio is presently 1.2 days. Approximately 0.2% of the shares of the company are short sold. Approximately 0.2% of the shares of the company are short sold. Based on an average daily trading volume, of 642,736 shares, the short-interest ratio is presently 1.2 days.

Provectus Biopharmaceuticals Price Performance

PVCT stock traded down $0.00 during trading on Monday, hitting $0.06. The company had a trading volume of 47,151 shares, compared to its average volume of 107,725. The company has a fifty day moving average price of $0.06 and a two-hundred day moving average price of $0.07. Provectus Biopharmaceuticals has a fifty-two week low of $0.05 and a fifty-two week high of $0.12.

Provectus Biopharmaceuticals Company Profile

Provectus Biopharmaceuticals, Inc is a U.S.-based clinical-stage biopharmaceutical company focused on the development and commercialization of immuno-oncology and tumor ablation therapies. Headquartered in Knoxville, Tennessee, the company’s lead investigational product is PV-10, a proprietary formulation of Rose Bengal disodium for intralesional injection. PV-10 is designed to selectively ablate tumor cells while stimulating a systemic immune response against cancerous lesions.

PV-10 has been evaluated in multiple clinical trials across a range of solid tumors, with key studies conducted in melanoma, hepatocellular carcinoma and other refractory cancers.